- Home
- SKYE vs BCBP Comparison
SKYE vs BCBP Comparison
Compare SKYE & BCBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- BCBP
- Stock Information
- Founded
- SKYE 2012
- BCBP 2000
- Country
- SKYE United States
- BCBP United States
- Employees
- SKYE N/A
- BCBP N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- BCBP Savings Institutions
- Sector
- SKYE Health Care
- BCBP Finance
- Exchange
- SKYE Nasdaq
- BCBP Nasdaq
- Market Cap
- SKYE 172.9M
- BCBP 211.6M
- IPO Year
- SKYE N/A
- BCBP N/A
- Fundamental
- Price
- SKYE $5.36
- BCBP $12.51
- Analyst Decision
- SKYE Strong Buy
- BCBP Hold
- Analyst Count
- SKYE 5
- BCBP 2
- Target Price
- SKYE $18.40
- BCBP $13.50
- AVG Volume (30 Days)
- SKYE 147.7K
- BCBP 52.5K
- Earning Date
- SKYE 11-09-2024
- BCBP 10-17-2024
- Dividend Yield
- SKYE N/A
- BCBP 5.13%
- EPS Growth
- SKYE N/A
- BCBP N/A
- EPS
- SKYE N/A
- BCBP 1.20
- Revenue
- SKYE N/A
- BCBP $91,235,000.00
- Revenue This Year
- SKYE N/A
- BCBP N/A
- Revenue Next Year
- SKYE N/A
- BCBP $10.69
- P/E Ratio
- SKYE N/A
- BCBP $10.44
- Revenue Growth
- SKYE N/A
- BCBP N/A
- 52 Week Low
- SKYE $1.44
- BCBP $9.19
- 52 Week High
- SKYE $19.41
- BCBP $13.90
- Technical
- Relative Strength Index (RSI)
- SKYE 46.06
- BCBP 63.50
- Support Level
- SKYE $5.71
- BCBP $11.66
- Resistance Level
- SKYE $7.11
- BCBP $12.08
- Average True Range (ATR)
- SKYE 0.56
- BCBP 0.28
- MACD
- SKYE -0.02
- BCBP 0.04
- Stochastic Oscillator
- SKYE 0.00
- BCBP 100.00
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About BCBP BCB Bancorp Inc. (NJ)
BCB Bancorp Inc is a bank holding company. The company offers loans, including commercial and multi-family real estate loans, home equity loans, construction loans, consumer loans, and commercial business loans; FDIC-insured deposit products, such as savings and club accounts, interest and non-interest bearing demand accounts, money market accounts, certificates of deposit and individual retirement accounts, and retail and commercial banking services, including wire transfers, money orders, safe deposit boxes, a night depository, debit cards, online banking, gift cards, fraud detection, and automated teller services.